6.5 C
New York
Monday, October 25, 2021

CDC adds two COVID-19 variants detected in California to “variants of concern” found to be 20% more infectious

Must Read

Jack Dorsey – CEO of Twitter warns: ‘Hyperinflation is going to change everything’ and ‘It’s happening’

The word "hyperinflation" used by the CEO of Twitter and Square is surprising Twitter...

In the US, a student party ended in a fatal shooting

Law enforcement officers are asking for help in "establishing those responsible for the shooting."

One of the US prisons has the largest COVID outbreak

No more than a dozen prisoners managed to get a vaccine against coronavirus infection in prison.
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

Two variants of coronavirus that were detected in California in the month of July and September have been added to the list of CDC’s ‘variants of concern’.  

Health experts consider that both variant are about 20% more infectious compare to the original’ variant, based on early data.

The find also points out that some antibody treatments may not work against both variants.  

As stated, the Department of Health and Human Services (HHS) will no longer deliver one of two antibody drugs made by Eli Lilly to California, Arizona or Nevada as the strains are so prevalent in these two states, drug may not work there.

In total, there are now 5 variants of concern (VOC), catching Americans, including two California variants, one British variant, one from South Africa and Brazil one.

However, none of these variants has been added to the ‘variant of high consequence,’ by the CDC.

But, the California strains, found in July and September – carrier of two mutations, with its four mutations is capable enough spreading its wings quickly.

Both variants account for more than half of all Covid cases in the state by February, according to estimates based on viral genome sequencing done by the University of California, San Francisco. 

The study authors pointed out that both variants may be responsible for 90 % of California’s cases by the end of this month. 

Over the entire course of the pandemic, the variant has been found in 7 percent of US samples. 

The slightly younger B1427 variant has been detected in 3 percent of samples submitted cumulatively. 

It was flagged found in 18 percent of samples from California submitted on March 5. 

B1427 has been detected in all US states except South Dakota, West Virginia, Vermont and Alaska. 

Already, it accounts for eight percent of samples submitted from Nevada. 

The more mutated B1429 variant is now in every single state except South Dakota and, according to Outbreak.info, it is even more prevalent in Nevada (24 percent) than in California (20 percent). 

Each has a mutation that makes it better at latching onto human cells, which makes it more easily transmissible.  

And antibody drugs that use just one type of antibody to treat infection, rather than two, may be less effective, early lab tests suggest. 

The HHS has paused shipments of Eli Lilly’s monoclonal antibody – meaning the drug contains just one lab-designed type of antibody – to California, Arizona and Nevada. 

Food and Drug Administration (FDA) regulators also updated the stipulations of the emergency use authorization – a form of temporary approval with a lower bar than full approval – for both of Eli Lilly’s antibody drugs and the one made by Regeneron to require the companies to ‘monitor’ variants that could weaken their treatments. 

As of yet there is no requirement for them to change the formulations of their the drugs, but there could be if the drugs are rendered ineffective by variants. 

So far, it appears that Eli Lilly’s other treatment, a combination of bamlanivimab and etesevimab still works against the California variant, as does Regeneron’s drug. Both treatments rae antibody ‘cocktails.’

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -